• Myriad Genetics announced MONSTAR-SCREEN-3 findings supporting its Precise MRD platform's potential to identify recurrence risk following colorectal and pancreatic cancer surgery.
• In colorectal cancer, the test detected molecular signs of recurrence before clinical surveillance in all observed recurrence cases.
• Pancreatic cancer patients with detectable residual disease following surgery had significantly worse recurrence-free survival than those without detectable disease.
• The findings will be presented at the European Society for Medical Oncology Congress on October 25, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220905PRIMZONEFULLFEED9851030) on October 22, 2026, and is solely responsible for the information contained therein.